Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
Study Shows Psoriatic Arthritis Impacts Women More Than Men
Psoriatic arthritis (PsA) has a higher life impact on women than men, suggesting the need to include life impact as part of the treat-to-target strategy for PsA. This is the finding of a recently published study by Orbai et al., which found female sex independently linked to high PsA life impact.1 The Study The study…
FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis
The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…
Guselkumab Approved for PsA
Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…
2 Pediatric Indications Sought for Golimumab
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis
Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…
Risankizumab & Apremilast Come to Market in Canada
In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…
Tildrakizumab Promising for Psoriasis in Patients with PsA
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…
Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
Rituximab-abbs, which is biosimilar to rituximab, is now available in the U.S. to treat specific cancers…
A Rash of Evidence: Evaluating & Treating Psoriatic Arthritis
ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 17
- Next Page »